Nexalin Technology

Nexalin Technology R&D per Employee

The R&D Spending per Employee of Nexalin Technology (NXL) as of Nov 11, 2026 is 180,587.00 USD. In the previous year, R&D Spending per Employee was 198,500.00 USD — a change of -9.02% (lower).

R&D per Employee

180,587.00USD

YoY

-9.02%

Last updated:

R&D Spending per Employee of Nexalin Technology is 2025 180,587.00 USD. R&D Spending per Employee of Nexalin Technology was 2024 198,500.00 USD. It decreases by -9.02% lower compared to the previous year.

The Nexalin Technology R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2021
23,166.67 USD
Jan 1, 2022
85,166.67 USD
Jan 1, 2023
320,333.33 USD
Jan 1, 2024
198,500.00 USD
Jan 1, 2025
180,587.00 USD
The Nexalin Technology R&D per Employee history
YEARR&D per EmployeeYoY
180,587.00USD-9.02%
198,500.00USD-38.03%
320,333.33USD+276.13%
85,166.67USD+267.63%
23,166.67USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nexalin Technology Stock analysis

What does Nexalin Technology do? Nexalin Technology, Inc. generates revenue through the sale of its neurostimulation products, specifically the Generation 1 or Gen-1 device, which treats anxiety and insomnia using bioelectronic medical technology without drugs or psychotherapy. The company's products are non-invasive and undetectable, targeting individuals with mental health issues seeking relief without adverse side effects. Nexalin designs clinical trials for Gen-2, aimed at treating substance use disorders, particularly opiate-related issues, chronic pain, Alzheimer’s disease, and dementia, though Gen-2 is not yet commercially available. The firm focuses on medical applications where traditional treatments may be less effective or carry risks. The primary buyers of Gen-1 are patients with anxiety and insomnia who prefer non-pharmacological solutions. The company’s marketing emphasizes the device’s ease of administration and lack of side effects, appealing to those dissatisfied with conventional treatments. Nexalin’s clinical trials for Gen-2 target healthcare providers and institutions treating substance use disorders, Alzheimer’s, and dementia, positioning the product for future market entry in these high-demand segments. The firm’s revenue model relies on direct sales of Gen-1 and anticipated future sales of Gen-2 once clinical trials are completed and regulatory approvals are secured. Nexalin’s products operate through a unique waveform technology that combines varying voltages, currents, electromagnetic fields, and frequencies applied via electrodes on the head. This technology differentiates the company in the medical device market by offering a non-invasive alternative to drug-based therapies. The company’s focus on mental health and neurological conditions aligns with growing demand for innovative, side-effect-free treatments, enabling it to target specific patient segments seeking alternatives to traditional pharmaceuticals. Nexalin Technology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nexalin Technology stock

R&D Spending per Employee of Nexalin Technology is 180,587.00 USD in 2025.

R&D Spending per Employee of Nexalin Technology changed from 198,500.00 USD to 180,587.00 USD, representing a -9.02% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Nexalin Technology since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Nexalin Technology historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Nexalin Technology

All Key Metrics — Nexalin Technology